MAP2K7 and colorectal carcinoma: Notably, a large phase III study of the MEK inhibitor cobimetinib and the anti-PD-L1 antibody atezolizumab in CRC failed to achieve its primary end point, which has cast doubt on whether MAPK pathway inhibition in general has the potential to enhance the immune response.